Evidence map›Paper›PMID 33993466›Full record

Trial reportBritish journal of haematology2021

Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome.

Richard W Childs, Xin Tian, Phuong Vo, Enkhtsetseg Purev, Ritesh R Kotecha, Mattias Carlsten, Joseph Clara, Willy A Flegel, Sharon D Adams, Hanh M Khuu and 8 more

Open access · bronzeAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. In 2022, which is preferred: haploidentical or cord transplant?Hematology. American Society of Hematology. Education Program · 2022
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Richard W ChildsNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Xin TianNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0003-1896-2462
Phuong VoNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Enkhtsetseg PurevNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Ritesh R KotechaNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Mattias CarlstenNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Joseph ClaraNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Willy A FlegelDepartment of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Sharon D AdamsDepartment of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Hanh M KhuuDepartment of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, MD, USA.
David F StroncekDepartment of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Lisa CookNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Tat'yana WorthyNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Nancy L GellerNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Brian WellsNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Jennifer WilderClinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD, USA.
Robert RegerNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Georg AueNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0003-2497-737X
National Institutes of Health · USNational Institutes of Health Clinical Center · USFrederick National Laboratory for Cancer Research · US

Funding

Allogeneic Immunotherapy for cancer and nonmalignant hematological disordersZIAHL002345 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI CHILDS, RICHARD · 2009 to 2025
$53.3M
Development of novel cell and gene therapiesZIACL002120 · CLC · CLINICAL CENTER · PI STRONCEK, DAVID · 2009 to 2025
$0k
Laboratory Services Section, Department of Transfusion Medicine Core ReportZICCL002128 · CLC · CLINICAL CENTER · PI FLEGEL, WILLY · 2020 to 2025
$0k
Intramural NIH HHS ZIC CL002128
6 · The paper itself

Abstract

Umbilical cord blood (UCB) transplantation is a potentially curative treatment for patients with refractory severe aplastic anaemia (SAA), but has historically been associated with delayed engraftment and high graft failure and mortality rates. We conducted a prospective phase 2 trial to assess outcome of an allogeneic transplant regimen that co-infused a single UCB unit with CD34

Indexed as

Anemia, AplasticCord Blood Stem Cell TransplantationGraft vs Host DiseaseHematopoietic Stem Cell TransplantationMyelodysplastic SyndromesAdolescentAdultChildChild, PreschoolDisease-Free SurvivalFemaleFollow-Up StudiesHumansIncidenceLeukocyte CountMaleallogeneic stem-cell transplantationhaploidentical transplantnatural killer cell killer-cell immunoglobulin-like receptor ligand incompatibilitysevere aplastic anaemiaumbilical cord blood

Identifiers

PMID33993466
PMCPMC9066776
OpenAlexW3163509569

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.